Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.50 – $3.51
6% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.22B | $8.93B | $9.08B | $9.07B | $9.98B | $10.98B | $11.29B | $11.00B |
| Cost of revenue | $4.55B | $5.04B | $4.95B | $4.86B | $5.77B | $6.24B | $6.39B | $6.32B |
| Gross profit | $3.66B | $3.89B | $4.13B | $4.21B | $4.21B | $4.74B | $4.91B | $4.68B |
| Gross margin | 44.6% | 43.5% | 45.5% | 46.4% | 42.2% | 43.1% | 43.4% | 42.6% |
| R&D | $141.0M | $139.0M | $114.0M | $100.0M | $115.0M | $149.0M | $150.0M | $132.7M |
| Operating income | $493.0M | $671.0M | $866.0M | $1.08B | $691.0M | $884.0M | $893.0M | $831.0M |
| EBITDA | $1.19B | $1.68B | $1.82B | $2.03B | $1.79B | $2.05B | $2.01B | $1.97B |
| Net income | $296.0M | $403.0M | $526.0M | $742.0M | $449.0M | $480.0M | $498.0M | $334.0M |
| Net margin | 3.6% | 4.5% | 5.8% | 8.2% | 4.5% | 4.4% | 4.4% | 3.0% |
| EPS (diluted) | 1.09 | 1.48 | 1.93 | 2.72 | 1.65 | 1.76 | 1.83 | 1.23 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11.0B | $1.79 | $1.78–$1.80 | 1 |
| 2027 | $11.4B | $2.10 | $2.08–$2.11 | 1 |
| 2028 | $11.8B | $2.35 | $2.33–$2.37 | 1 |
| 2029 | $12.0B | $2.21 | $2.19–$2.22 | 1 |
Forward consensus · source: Financial Modeling Prep
ARJO AB
No one on the platform currently holds ARRJF.
No tracked institution reports a position in ARRJF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-24 | $0.9500 | 2026-04-29 |
| 2025-05-02 | $0.9500 | 2025-05-07 |
| 2024-04-19 | $0.9000 | 2024-04-25 |
No one on the platform has traded ARRJF yet.
| $185M |
| — |
| RKAGYRHON-KLINIKUM AG Unsponsored ADR | $8.16 | +0.00% | $1.1B | — |
| SAFLFSafilo Group S.p.A. | $2.01 | +0.00% | $790M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.5× earnings vs its 2.5× historical median P/E.
Fair value ≈ $4.25 · price $2.56 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.